Biblio

Export 421 results:
Author Keyword Title [ Type(Desc)] Year
Filters: Keyword is Alzheimer Disease  [Clear All Filters]
Journal Article
K. Le Guennec, Tubeuf, H., Hannequin, D., Wallon, D., Quenez, O., Rousseau, S., Richard, A. - C., Deleuze, J. - F., Boland, A., Frebourg, T., Gaildrat, P., Campion, D., Martins, A., and Nicolas, G., “Biallelic Loss of Function of SORL1 in an Early Onset Alzheimer's Disease Patient.”, J Alzheimers Dis, vol. 62, no. 2, pp. 821-831, 2018.
A. Mulak, “Bile Acids as Key Modulators of the Brain-Gut-Microbiota Axis in Alzheimer's Disease.”, J Alzheimers Dis, vol. 84, no. 2, pp. 461-477, 2021.
T. Dziedzic, Pera, J., Klimkowicz-Mrowiec, A., Mroczko, B., and Slowik, A., “Biochemical and Radiological Markers of Alzheimer's Disease Progression.”, J Alzheimers Dis, vol. 50, no. 3, pp. 623-44, 2016.
I. Koychev, Jansen, K., Dette, A., Shi, L., and Holling, H., “Blood-Based ATN Biomarkers of Alzheimer's Disease: A Meta-Analysis.”, J Alzheimers Dis, vol. 79, no. 1, pp. 177-195, 2021.
A. Malishkevich, Marshall, G. A., Schultz, A. P., Sperling, R. A., Aharon-Peretz, J., and Gozes, I., “Blood-Borne Activity-Dependent Neuroprotective Protein (ADNP) is Correlated with Premorbid Intelligence, Clinical Stage, and Alzheimer's Disease Biomarkers.”, J Alzheimers Dis, vol. 50, no. 1, pp. 249-60, 2016.
F. Guillot, Kemppainen, S., Lavasseur, G., Miettinen, P. O., Laroche, S., Tanila, H., and Davis, S., “Brain-Specific Basal and Novelty-Induced Alternations in PI3K-Akt and MAPK/ERK Signaling in a Middle-Aged AβPP/PS1 Mouse Model of Alzheimer's Disease.”, J Alzheimers Dis, vol. 51, no. 4, pp. 1157-73, 2016.
H. - F. Wang, Wan, Y., Hao, X. - K., Cao, L., Zhu, X. - C., Jiang, T., Tan, M. - S., Tan, L., Zhang, D. - Q., Tan, L., and Yu, J. - T., “Bridging Integrator 1 (BIN1) Genotypes Mediate Alzheimer's Disease Risk by Altering Neuronal Degeneration.”, J Alzheimers Dis, vol. 52, no. 1, pp. 179-90, 2016.
I. A. Clark and Vissel, B., “Broader Insights into Understanding Tumor Necrosis Factor and Neurodegenerative Disease Pathogenesis Infer New Therapeutic Approaches.”, J Alzheimers Dis, vol. 79, no. 3, pp. 931-948, 2021.
H. Khodadadi, Salles, É. Lopes, Jarrahi, A., Costigliola, V., Khan, M. B., Yu, J. C., Morgan, J. C., Hess, D. C., Vaibhav, K., Dhandapani, K. M., and Baban, B., “Cannabidiol Ameliorates Cognitive Function via Regulation of IL-33 and TREM2 Upregulation in a Murine Model of Alzheimer's Disease.”, J Alzheimers Dis, vol. 80, no. 3, pp. 973-977, 2021.
E. Aso, Andrés-Benito, P., Carmona, M., Maldonado, R., and Ferrer, I., “Cannabinoid Receptor 2 Participates in Amyloid-β Processing in a Mouse Model of Alzheimer's Disease but Plays a Minor Role in the Therapeutic Properties of a Cannabis-Based Medicine.”, J Alzheimers Dis, vol. 51, no. 2, pp. 489-500, 2016.
M. Mäkelä, Paetau, A., Polvikoski, T., Myllykangas, L., and Tanskanen, M., “Capillary amyloid-β protein deposition in a population-based study (Vantaa 85+).”, J Alzheimers Dis, vol. 49, no. 1, pp. 149-57, 2016.
K. Ding, Tarumi, T., Zhu, D. C., Tseng, B. Y., Thomas, B. P., Turner, M., Repshas, J., Kerwin, D. R., Womack, K. B., Lu, H., C Cullum, M., and Zhang, R., “Cardiorespiratory Fitness and White Matter Neuronal Fiber Integrity in Mild Cognitive Impairment.”, J Alzheimers Dis, vol. 61, no. 2, pp. 729-739, 2018.
M. A. Burguillos, Deierborg, T., Kavanagh, E., Persson, A., Hajji, N., Garcia-Quintanilla, A., Cano, J., Brundin, P., Englund, E., Venero, J. L., and Joseph, B., “Caspase signalling controls microglia activation and neurotoxicity.”, Nature, vol. 472, no. 7343, pp. 319-24, 2011.
D. Renard, Wacongne, A., Ayrignac, X., Charif, M., Fourcade, G., Azakri, S., Le Floch, A., Bouly, S., Marelli, C., Arquizan, C., Hirtz, C., Gabelle, A., Thouvenot, E., and Lehmann, S., “Cerebrospinal Fluid Alzheimer's Disease Biomarkers in Cerebral Amyloid Angiopathy-Related Inflammation.”, J Alzheimers Dis, vol. 50, no. 3, pp. 759-64, 2016.
D. - W. Chen, Wang, J., Zhang, L. - L., Wang, Y. - J., and Gao, C. - Y., “Cerebrospinal Fluid Amyloid-β Levels are Increased in Patients with Insomnia.”, J Alzheimers Dis, vol. 61, no. 2, pp. 645-651, 2018.
A. Kimura, Yoshikura, N., Hayashi, Y., and Inuzuka, T., “Cerebrospinal Fluid C-C Motif Chemokine Ligand 2 Correlates with Brain Atrophy and Cognitive Impairment in Alzheimer's Disease.”, J Alzheimers Dis, vol. 61, no. 2, pp. 581-588, 2018.
P. Buchhave, Minthon, L., Zetterberg, H., Wallin, A. K., Blennow, K., and Hansson, O., “Cerebrospinal fluid levels of β-amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia.”, Arch Gen Psychiatry, vol. 69, no. 1, pp. 98-106, 2012.
K. E. Melah, Lu, S. Yuan- Fu, Hoscheidt, S. M., Alexander, A. L., Adluru, N., Destiche, D. J., Carlsson, C. M., Zetterberg, H., Blennow, K., Okonkwo, O. C., Gleason, C. E., N Dowling, M., Bratzke, L. C., Rowley, H. A., Sager, M. A., Asthana, S., Johnson, S. C., and Bendlin, B. B., “Cerebrospinal Fluid Markers of Alzheimer's Disease Pathology and Microglial Activation are Associated with Altered White Matter Microstructure in Asymptomatic Adults at Risk for Alzheimer's Disease.”, J Alzheimers Dis, vol. 50, no. 3, pp. 873-86, 2016.
G. Novak, Fox, N., Clegg, S., Nielsen, C., Einstein, S., Lu, Y., Tudor, I. Cristina, Gregg, K., Di, J., Collins, P., Wyman, B. T., Yuen, E., Grundman, M., H Brashear, R., and Liu, E., “Changes in Brain Volume with Bapineuzumab in Mild to Moderate Alzheimer's Disease.”, J Alzheimers Dis, vol. 49, no. 4, pp. 1123-34, 2016.
O. Godefroy, Bakchine, S., Verny, M., Delabrousse-Mayoux, J. - P., Roussel, M., and Pere, J. - J., “Characteristics of Alzheimer's Disease Patients with Severe Executive Disorders.”, J Alzheimers Dis, vol. 51, no. 3, pp. 815-25, 2016.
A. Madhavan, Schwarz, C. G., Duffy, J. R., Strand, E. A., Machulda, M. M., Drubach, D. A., Kantarci, K., Przybelski, S. A., Reid, R. I., Senjem, M. L., Gunter, J. L., Apostolova, L. G., Lowe, V. J., Petersen, R. C., Jack, C. R., Josephs, K. A., and Whitwell, J. L., “Characterizing White Matter Tract Degeneration in Syndromic Variants of Alzheimer's Disease: A Diffusion Tensor Imaging Study.”, J Alzheimers Dis, vol. 49, no. 3, pp. 633-43, 2016.
H. - L. Wang, Wang, Y. - Y., Liu, X. - G., Kuo, S. - H., Liu, N., Song, Q. - Y., and Wang, M. - W., “Cholesterol, 24-Hydroxycholesterol, and 27-Hydroxycholesterol as Surrogate Biomarkers in Cerebrospinal Fluid in Mild Cognitive Impairment and Alzheimer's Disease: A Meta-Analysis.”, J Alzheimers Dis, vol. 51, no. 1, pp. 45-55, 2016.
D. E. Moss, Perez, R. G., and Kobayashi, H., “Cholinesterase Inhibitor Therapy in Alzheimer's Disease: The Limits and Tolerability of Irreversible CNS-Selective Acetylcholinesterase Inhibition in Primates.”, J Alzheimers Dis, vol. 55, no. 3, pp. 1285-1294, 2017.
H. Qiu, Zhong, R., Liu, H., Zhang, F., Li, S., and Le, W., “Chronic Sleep Deprivation Exacerbates Learning-Memory Disability and Alzheimer's Disease-Like Pathologies in AβPP(swe)/PS1(ΔE9) Mice.”, J Alzheimers Dis, vol. 50, no. 3, pp. 669-85, 2016.
K. R. LeVault, Tischkau, S. A., and Brewer, G. J., “Circadian Disruption Reveals a Correlation of an Oxidative GSH/GSSG Redox Shift with Learning and Impaired Memory in an Alzheimer's Disease Mouse Model.”, J Alzheimers Dis, vol. 49, no. 2, pp. 301-16, 2016.

Pages